Results 191 to 200 of about 202,254 (242)

Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report. [PDF]

Front Oncol
Martinez-Gamboa DA, Beas FF, Moreno-Cortes E, Swanson LA, Mangold AR, Vargas F, Castro JE.   +6 more
europepmc   +1 more source

Diffuse Large B-Cell Lymphoma Combined With Paroxysmal Nocturnal Hemoglobinuria: A Rare Case Report. [PDF]

Clin Case Rep
Liu ZZ, Di DL, Feng AH, Yu J, Wang HY, Qin L.   +5 more
europepmc   +1 more source

Correction: EZH2 suppresses the chemosensitivity of diffuse large B cell lymphoma via regulating TP53INP1. [PDF]

Clin Exp Med
Gu J, Chen T, Gao S, Long T.
europepmc   +1 more source

XBP1-driven proliferative B cell subcluster in Diffuse Large B Cell Lymphoma linked to altered nucleotide metabolism. [PDF]

Eur J Med Res
Ma L, Wang J, Zhao J, Wang J, Wen X, Zheng M, Su L.   +6 more
europepmc   +1 more source

Prebiopsy Steroids and Diagnostic Yield in Patients With Diffuse Large B-Cell Lymphoma.

JAMA Netw Open
Madireddy S, Pou S, Mandi K, Pan K, Friefeld A, Ding HH, Raker C, Terada R, Milrod CJ, Pelcovits A.   +9 more
europepmc   +1 more source

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma. [PDF]

Future Oncol
Johnson NA, Zinzani PL, Domingo-Domenech E, Brody J, Kline J, Shah BD, Mehta AN, Ghesquieres H, Savage KJ, Barr PM, Santoro A, Ferrari S, Cunningham D, Collins GP, Fanale M, Krajewski J, Akyol A, Crowe R, Wen R, Kuruvilla J.   +19 more
europepmc   +1 more source

CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma. [PDF]

Front Immunol
Rodríguez M, Rojas-Vega F, Díaz-Alejo JF, Mahillo-Fernández I, Serrano C, López A, Morales-Ruiz T, Roldan-Arjona T, Sánchez-García J, Río-Machín A, Morillo D, Pérez MA, Córdoba R, Llamas-Sillero P, Rodríguez-Pinilla SM, Serrano-López J.   +15 more
europepmc   +1 more source